Adam Savitz Biography and Net Worth

Insider of Alto Neuroscience

Dr. Adam Savitz has served as our Chief Medical Officer since July 2021. Before joining us, Dr. Savitz served in various roles at Janssen Research and Development, LLC, a pharmaceutical company, from May 2011 to June 2021, most recently serving as Senior Director Clinical Research from July 2017 to June 2021. From 2020 to 2021, he served as Clinical Strategy Leader for the Mood Disorder Disease Area Stronghold. Dr. Savitz completed his psychiatry training and served on the staff at Massachusetts General Hospital. He served as a full-time faculty member in the Department of Psychiatry at Weill Cornell Medicine, including as unit chief of an inpatient psychiatry unit, from 2001 until 2011. He received an MD and a PhD in molecular biology at the University of California, Los Angeles, and a BS/MS in molecular biophysics and biochemistry from Yale University.

What is Adam Savitz's net worth?: The estimated net worth of Adam Savitz is at least $810.87 thousand as of July 9th, 2024. Savitz owns 36,920 shares of Alto Neuroscience stock worth more than $810,874 as of October 25th. This net worth evaluation does not reflect any other investments that Savitz may own. Learn More about Adam Savitz's net worth.
How do I contact Adam Savitz?: The corporate mailing address for Savitz and other Alto Neuroscience executives is 650 Castro Street, Suite 450, Mountain View, CA, 94041. Alto Neuroscience can also be reached via phone at (773) 255-5012 and via email at [email protected]. Learn More on Adam Savitz's contact information.
Has Adam Savitz been buying or selling shares of Alto Neuroscience?: Adam Savitz has not been actively trading shares of Alto Neuroscience over the course of the past ninety days. Most recently, on Tuesday, July 9th, Adam Savitz bought 12,069 shares of Alto Neuroscience stock. The stock was acquired at an average cost of $12.60 per share, with a total value of $152,069.40. Following the completion of the transaction, the insider now directly owns 36,920 shares of the company's stock, valued at $465,192. Learn More on Adam Savitz's trading history.
Who are Alto Neuroscience's active insiders?: Alto Neuroscience's insider roster includes Adam Savitz (Insider), and Nicholas Smith (CFO). Learn More on Alto Neuroscience's active insiders.
Are insiders buying or selling shares of Alto Neuroscience?: During the last year, insiders at the sold shares 2 times. They sold a total of 134,886 shares worth more than $3,566,987.32. The most recent insider tranaction occured on September, 30th when CFO Nicholas Conrad Smith sold 24,056 shares worth more than $621,125.92. Insiders at Alto Neuroscience own 11.3% of the company. Learn More about insider trades at Alto Neuroscience.
Information on this page was last updated on 9/30/2026.

Adam Savitz Insider Trading History at Alto Neuroscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/9/2024	Buy	12,069	$12.60	$152,069.40	36,920

Adam Savitz Buying and Selling Activity at Alto Neuroscience

Alto Neuroscience Company Overview

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Today's Range

Now: $21.96

$21.45

$22.45

50 Day Range

MA: $29.45

$21.70

$36.75

2 Week Range

Now: $21.96

$10.20

$37.48

Volume

379,246 shs

Average Volume

681,517 shs

Market Capitalization

$861.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31